Among new molecules on the horizon for the treatment of overweight and obesity, the most promising appears to be tirzepatide (LY3298176), an incretin mimetic with a dual action targeting both the GLP1 receptor and the glucosedependent insulinotropic polypeptide (GIP) receptor 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 (Figure 2 and Supplementary Figure 1)
The FDA is not aware of any basis for compounding using the salt forms that would meet the FD&C Act conditions for types of active ingredients that can be used in compounding.
Moreover, dont hesitate to reach out to your healthcare provider for personalized advice and adjustments to your treatment plan
So, what are the critical steps to ensure a successful mixing process, and how can you avoid common pitfalls
Here are the warning signs you should never ignore